Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on BioCryst. The associated price target remains the same with $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein’s rating is based on BioCryst’s strategic acquisition of Astria Therapeutics, which is seen as a timely move to enhance its hereditary angioedema (HAE) portfolio. By acquiring navenibart, a Phase 3 long-acting monoclonal antibody inhibitor, BioCryst is positioning itself to offer patients an alternative to daily oral therapy with a potentially twice-yearly injectable. This acquisition complements BioCryst’s existing oral option, Orladeyo, allowing the company to provide a comprehensive range of prophylactic treatments for HAE, thus strengthening its market position.
Furthermore, the acquisition aligns with BioCryst’s strategy to consolidate its leadership in the HAE space and capitalize on the long-term profitability of this therapeutic area. The addition of navenibart is expected to benefit from BioCryst’s established commercialization infrastructure, providing significant operating synergies and immediate upside post-launch. This move is anticipated to solidify BioCryst’s growth trajectory in the HAE market over the next decade, offering both convenience and efficacy to a broader patient base.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year.